5:06 PM
Feb 01, 2010
 |  BC Extra  |  Company News

FDA panel to discuss pirfenidone

FDA's Pulmonary-Allergy Drug Advisory Committee will meet on March 9 to discuss an NDA from InterMune Inc. (NASDAQ:ITMN) for pirfenidone to treat idiopathic pulmonary...

Read the full 102 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >